The antibody, administered at repeated doses of up to 8 mg-kg, was generally well tolerated, and the pharmacokinetic characteristics of BTT-1023 in psoriasis patients were consistent with those observed in a previously completed study in rheumatoid arthritis RA patients. This promising development showcases the positive potential impact of BTT-1023 in treating psoriasis patients, reflecting a favorable outlook for the medication's efficacy and safety.